Datroway has been approved in the U.S. for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer who have received prior EGFR-directed therapy and platinum-based chemotherapy. This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca reports Datroway approved in U.S. for EGFR-mutated NSCLC
- AstraZeneca’s Promising Pipeline and Upcoming Catalysts Drive Buy Rating
- Trump administration weighs crackdown on pharma ads, Bloomberg says
- AstraZeneca and CSPC Forge AI-Driven Drug Discovery Partnership
- AstraZeneca enters strategic collaboration with CSPC Pharmaceuticals
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue